drugset / Trial / NCT06868654
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Chinese participants with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2021-07-28
- Primary completion
- 2024-04-03
- Completion
- 2028-06-30
Outcome
Met primary endpoint
registry analysis (other test); Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) vs Daratumumab + Bor + Dex; Hazard Ratio (HR) 0.24 (95% CI 0.11 to 0.56) NCT06868654 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belantamab mafodotin | Monoclonal antibody | — | — |
| Comparator | Daratumumab | Monoclonal antibody | — | — |
| Background | Bortezomib | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |